Therapeutic agents inhibiting pro-fibrotic TGF-β1/Smad2/3 signaling could prevent renal fibrosis 94, liver fibrosis 95, 96, pulmonary fibrosis 97, 98, and cardiac fibrosis 99-101. The gene discussed is SMAD2; the disease is Hepatic fibrosis.